John Rex, MD, chief medical officer at drug discovery company F2G, told Becker’s he also feels the solution is two-part: legislative and research-driven.

If data is the new oil, CytoReason is one of its barons. Combining all available information about a disease – literature, data sets, all data types – the company builds computational disease models utilized by its pharma partners to help them determine which drug avenues to pursue next.

Elicio is merging with Angion Biomedica, a Uniondale, NY-based biotech that began searching for strategic alternatives last July after Phase II setbacks forced it to shutter all R&D work.

In 2021, PepGen raised $113 million to challenge Sarepta in DMD and build its neuromuscular and neurologic pipeline.

AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.

French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic.

Brian Wiley, chief business officer at Portage Biotech, spoke of striking a balance between in-person and virtual meetings.

Biotech company F2G announced today the FDA has accepted its NDA filing for its antifungal therapy, Olorofim. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for June 17, 2023.